Advanced search
Publication Cover
Leukemia & Lymphoma Volume 51, 2010 - Issue 9
Submit an article Journal homepage
571
Views
14
CrossRef citations to date
0
Altmetric
Letters to the Editor

Rituximab–lenalidomide–dexamethasone induces complete and durable remission in relapsed refractory diffuse large B-cell non-Hodgkin lymphoma

Vadim IvanovDepartment of Hematology, Institute Paoli-Calmettes, Marseille, FranceCorrespondence[email protected]
,
Emeline TabouretDepartment of Hematology, Institute Paoli-Calmettes, Marseille, France
,
Guillaume ChutoDepartment of Nuclear Medicine, Institute Paoli-Calmettes, Marseille, France
,
Bruno ChetailleDepartment of Pathology, Institute Paoli-Calmettes, Marseille, France
,
Hacène FezouiHopital Font Pré, Toulon, France
,
Diane CosoDepartment of Hematology, Institute Paoli-Calmettes, Marseille, France
,
Jerome ReyDepartment of Hematology, Institute Paoli-Calmettes, Marseille, France
,
Therese Aurran-SchleinitzDepartment of Hematology, Institute Paoli-Calmettes, Marseille, France
,
Jean Marc SchianoDepartment of Hematology, Institute Paoli-Calmettes, Marseille, France
,
Anne Marie StoppaDepartment of Hematology, Institute Paoli-Calmettes, Marseille, France
,
Didier Blaise
&
Reda BouabdallahDepartment of Hematology, Institute Paoli-Calmettes, Marseille, France
 show all
Pages 1-3 | Published online: 14 Jul 2010

References

  • Witzig TE, Vose JM, Kaplan HP, et al Early results from a phase II study of lenalidomide monotherapy in relapsed/refractory indolent non-Hodgkin's lymphoma. Blood 2006;108(Suppl. 1): (Abstract 2482).
  • Wiernik PH, Lossos I, Tuscano J, et al Preliminary results from a phase II study of lenalidomide monotherapy in relapsed/refractory aggressive non-Hodgkin's lymphoma. Blood 2006;108(Suppl. 1): (Abstract 531).
  • Wiernik PH, Lossos IS, Tuscano JM, et al Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 2008;26:4952–4957.
  • Witzig TE, Vose JM, Zinzani PL, et al Durable responses after lenalidomide oral monotherapy in patients with relapsed or refractory (R/R) aggressive non-Hodgkin's lymphoma (a-NHL): results from an international phase 2 study (CC-5013-NHL-003). Blood 2009;114(Suppl. 1): (Abstract 1676).
  • Habermann TM, Lossos IS, Justice G, et al Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 2009;145:344–349.
  • Hans CP, Weisenburger DD, Greiner TC, et al Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004;103:275–282.
  • Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4:314–322.
  • Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res 2005;11:5984–5992.
  • Wu L, Adams M, Carter T, et al Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res 2008;14:4650–4657.
  • Zhang L, Qian Z, Cai Z, et al Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol 2009;84:553–559.
  • Kaufmann H, Raderer M, Wohrer S, et al Antitumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma. Blood 2004;104:2269–2271.
  • Wang L, Fayad L, Hagemeister FB, et al A phase I/II study of lenalidomide in combination with rituximab in relapsed/refractory mantle cell lymphoma. Blood 2009;114(Suppl. 1): (Abstract 2719).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.